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ABSTRACT
As part of the 2019 Immunotherapy Bridge congress 
(December 4–5, Naples, Italy), the Great Debate session 
featured counterpoint views from leading experts on six 
topical issues in immunotherapy today. These were the 
use of chimeric antigen receptor T cell therapy in solid 
tumors, whether the Immunoscore should be more widely 
used in clinical practice, whether antibody- dependent 
cellular cytotoxicity is important in the mode of action 
of anticytotoxic T- lymphocyte- associated protein 4 
antibodies, whether the brain is immunologically unique 
or just another organ, the role of microbiome versus 
nutrition in affecting responses to immunotherapy, 
and whether chemotherapy is immunostimulatory or 
immunosuppressive. Discussion of these important topics 
are summarized in this report.
INTRODUCTION
Over recent years, extensive research has 
improved our understanding of tumor immu-
nology and enabled the development of novel 
treatments that can harness the patient’s 
immune system and prevent immune escape. 
Through numerous clinical trials and real- 
world experience, a large body of evidence 
of the potential for long- term survival with 
immunotherapy agents has been accumu-
lated across various types of malignancies, 
starting in melanoma and extending to 
other tumors. Organized by the Fondazione 
Melanoma Onlus, Naples, Italy, the Immu-
notherapy Bridge Congress was first held in 
2015 to provide a forum for international 
experts to discuss new approaches and strat-
egies in the field of immunotherapy. As part 
of the fifth Immunotherapy Bridge congress 
(December 4–5, 2019, Naples, Italy), the 
Great Debate session featured counterpoint 
views from invited leading experts on six 
topical issues in immunotherapy today. These 
were the use of chimeric antigen receptor 
(CAR) T cell therapy in solid tumors, whether 
the Immunoscore in colon cancer should be 
more widely used in clinical practice, whether 
antibody- dependent cellular cytotoxicity 
(ADCC) is important in the mode of action 
of anticytotoxic T- lymphocyte- associated 
protein 4 (anti- CTLA-4) antibodies, whether 
the brain is immunologically unique or just 
another organ, the role of microbiome versus 
nutrition in affecting responses to immu-
notherapy and whether chemotherapy is 
immunostimulatory or immunosuppressive. 
Discussion of these important topics are 
summarized in this report.
USE OF CAR T IN SOLID TUMORS: YES OR NO
Kunle Odunsi: yes
The cancer immunity cycle involves several 
stages that starts with release of cancer cell 
antigens, through priming, activation, traf-
ficking and infiltration of T cells into tumors 
and finally tumor disruption. The use of CAR 
T cell or transgenic T cell receptor (TCR) 
therapy bypasses many of these steps and the 
success of this approach has revolutionized 
the treatment of several hematological malig-
nancies. Now, there is increasing focus on 
the potential role of CAR T therapy for solid 
tumors.
The first question over the use of CAR T in 
solid tumors is what are we asking T cells to 
achieve? In liquid tumors, the tumor micro-
environment (TME) is peripheral blood so 
it is reasonably straightforward for T cells 
to mediate their effects. However, in solid 
tumors T cells have to successfully traffic 
from the blood into solid tumors despite 
potential T cell chemokine receptor umor- 
derived chemokine mismatches. T cells 
then have to infiltrate the stromal elements 
of solid tumors in order to elicit tumor- 
associated antigen (TAA)- specific cytotox-
icity. Even after successful trafficking and 
infiltration, T cells become rapidly dysfunc-
tional owing to a TME that is hostile because 
of multiple metabolic, inhibitory and 
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immunosuppressive factors, along with the issue of TAA 
loss or heterogeneity.
The ideal TAA for CAR T therapy in solid tumors should 
be selectively expressed on the surface of tumor cells 
at high levels, but not at all or at very low levels on the 
surface of normal tissues. Expression should be homoge-
neous and ideally across all tumor cells. The degree of 
specificity is also critical for safety, with the most feared 
complication of CAR therapy catastrophic and rapid on 
target- off tumor events than have the potential to be fatal. 
To date, a wide range of different target antigens have 
been used in clinical trials. None so far is ideal but we are 
learning how to refine strategies to better identify suitable 
targets.
Varying clinical outcomes have been reported across 
solid tumor antigen targets. CAR T cells specific to GD2 
resulted in 3 of 11 patients with neuroblastoma having 
complete remissions, HER2 CARs for sarcoma resulted in 
4 of 17 patients showing stable disease and 2 of 11 patients 
with lung cancer had partial responses with HER1 CARs.1 
These results suggest at least a hint that CAR T therapy 
may have potentially use in solid tumors.
The safety of CAR T therapy is a key issue and can only 
really be established in careful clinical trials. Possible solu-
tions for improving safety include the use of ‘self- limited’ 
CAR cells which employ mRNA electroporation rather 
than lentivirus to transiently express the CAR receptor, 
or the insertion of suicide genes that can be activated 
in case of adverse events, for example, HSV- TK gene or 
inducible caspase 9 gene. It is also possible to increase 
the specificity of CARs by requiring two antigens to be 
recognized to promote activity or to use combinatorial 
recognition circuits (eg, synthetic Notch receptors). All 
these approaches can help to mitigate the risk of fatal 
outcomes.
TAA heterogeneity can be addressed by targeting 
multiple antigens at once, as shown by CARs targeting 
both CD19 and CD20 in B cell leukemia, which provides 
better ‘killing coverage’ and may prevent the develop-
ment of resistance. Another approach is to use multi-
functional CARs which can encode by- products, such as 
cytokines, to augment tumor killing.
CAR antigens have to be expressed on the cell surface 
but most solid tumor antigens are intracellular, so lessons 
can be learned from the use of TCR transgenic T cells. 
The first report of autologous T cells transduced with 
a TCR directed against the NY- ESO-1 antigen showed 
remarkable tumor regression in patients with synovial 
cell sarcoma or metastatic melanoma.2 Patients who 
demonstrated responses to therapy were those with T 
cell persistence. Poor persistence of transferred CD8+ 
cells and insufficient CD4+ T cell support are two key chal-
lenges of adoptive T cell therapy. In a currently ongoing 
trial (NCT03691376), autologous engineered hemato-
poietic stem cells with tumor- recognizing CD4 TCRs are 
being used for long- term support of NY- ESO-1 CD8 TCR 
transduced T cells in recurrent or treatment- refractory 
ovarian cancer, with the aim of promoting long- term 
persistence of TCR T cells. Relevance of this to CAR T 
is that persistence of CAR T cells may be improved by 
harnessing the differentiation stage in vivo. One strategy 
to address intracellular antigens is to generate TCR- 
mimic cells. For example, T cells modified to express the 
TCR- mimic CAR, WT1- 28z, directed against the peptide 
portion of the intracellular onco- protein Wilms tumor 
1 (WT1), specifically targeted and lysed HLA- A*02:01+, 
WT1+ tumors and enhanced survival of mice engrafted 
with HLA- A*02:01+, WT1+ tumors.3
With regard to T cell trafficking, it may be possible to 
harness our understanding of immune cell chemotaxis 
and migration in novel ways in order to generate T cell 
detection and homing circuits. This may involve using 
CARs that co- express chemokine receptors resulting in 
increased intratumoral migration of CAR T cells and 
tumor eradication. Oncolytic viruses that encode tumor 
targets and chemokines may also be used. In addition, 
the local injection of CARs into tumors is being explored 
in clinical trials in liver, head and neck and other cancers.
Various strategies can be used to help CARs survive a 
hostile solid TME.4 Physical and metabolic barriers can be 
overcome by CARs that deplete fibroblast cells or degrade 
the extracellular matrix. Tumor- derived soluble factors 
and cytokines may be overcome by CARs that interrupt 
inhibitory adenosine and PGE2 signaling, or that express 
dominant negative transforming growth factor (TGF)-β. 
Simultaneous depletion of immunosuppressive immune 
cells may be achieved by the use of alternative homeo-
static cytokines, such as interleukin (IL)-7 and IL-21, to 
boost CAR efficacy without stimulating regulatory T cells 
(Tregs). Intrinsic regulatory mechanisms of T cells may be 
addressed by combining CAR therapy and programmed 
death-1 (PD-1) blockade, the use of PD-1 switch receptors 
to neutralize inhibitory PD-1 signaling, blocking CTLA-4 
enhanced adoptive transfer, or engineering CAR T cells 
lacking inhibitory molecules (eg, diacylglycerol kinase).
Toxicities may be controlled by user- controlled regula-
tory strategies that potentially allow a physician to modu-
late the survival of T cells, as well as the timing, strength 
and location of their activity. In addition, it may be possible 
to insert feedback control systems into therapeutic T cells 
which allow them to autonomously monitor when adverse 
outcomes reach a critical stage. Various other immuno- 
engineering advances are also being developed to further 
improve CAR T efficacy and safety.5
The ultimate goal of engineered immune cells (CAR T, 
TCR T) is to provide a reliable, safe and effective platform 
for treating cancer. Individual cancer types may present 
different challenges, and the types of engineered T cells 
that they need may be different. However, advances in 
synthetic biology and genome engineering are providing 
powerful tools to address the engineering needs of T cell 
therapy.
Chrystal M Paulos: no
CAR T cell therapies have been successful in hemato-
logic malignancies but have been less effective to date in 
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treating patients with solid tumors (figure 1). Anti- PD-1, 
anti- CTLA-4 therapies as well as the transfer or tumor- 
infiltrating lymphocytes (TIL) have been successful 
across many solid tumors and strategies involving these 
in combination with one another and other immunother-
apies may be a more worthwhile and feasible approach 
than pursuing the use of CAR T cells. This is not to say 
CAR T cells may not have a place in the treatment of solid 
tumors, but rather that other options may be more viable. 
This may be especially for those patients who do not have 
easy access to the expertise increasingly concentrated at 
major cancer centers.
Theoretically, CAR T therapies could have a role in 
the treatment of solid tumors but this will be an uphill 
challenge. There is a difficulty in designing a CAR 
against an antigen expressed only in the tumor and 
not in normal tissue. To date, clinical trials with CAR 
T cells in solid tumors have often demonstrated severe 
off- tumor toxicities since the targeted antigens are not 
completely foreign to the host, and even low expression 
in normal tissue can result in serious adverse effects.5 
Some TAAs have been identified that result in more 
limited off- tumor effects, but many of these targets 
for CAR T cells have shown poor clinical efficacy in 
patients, with disease stabilization the best response in 
many cases. In addition, solid tumors treated with CAR 
T cells may undergo antigen escape due to selection 
pressure that favors tumor cells lacking the targeted 
antigen. This highlights the major problem of tumor 
heterogeneity for solid tumor CAR treatments.
Even if the ideal solid tumor antigen could be iden-
tified and targeted, CAR T cell therapies face further 
obstacles including poor trafficking to the tumor site, 
difficulties in penetrating and infiltrating the tumor and 
limited persistence and proliferation within the host. 
Moreover, CAR T cells that can infiltrate the tumor can 
be functionally suppressed within a hostile TME, which 
is rich in suppressor cytokines, such as TGF-β and IL-4, 
and inhibitory molecules including programmed death 
ligand-1 (PD- L1). Activated CAR T cells within the TME 
express high concentrations of exhaustion markers 
such as PD-1, Tim-3, Lag3 and 2B4, indicative of the 
challenging TME.
It should also be noted that, although the periph-
eral blood is a much more welcoming environment for 
CAR T cells, the use of CAR therapies in hematolog-
ical malignancies has not always succeeded. However, 
there has been a tendency for these failures to be less 
widely discussed compared with successes, with the 
possible result that, even in liquid tumors, the potential 
of CAR T therapies may be overstated. In solid tumors, 
CAR T therapy has many significant challenges to over-
come. Although various bioengineering approaches are 
being tested to overcome these obstacles, it is not yet 
known whether these may be effective. It may be that 
TIL- based adoptive cell transfer together with cancer 
vaccines and anti- PD- 1s represent more feasible thera-
peutic approaches. However, it is important to recog-
nize that CAR T cell development for patients with solid 
tumors is still at an early stage. A danger is that CAR 
T cell therapy for solid tumors will be dismissed after 
a few failed trials, even though it may still represent a 
promising platform.
Key points
 ► CAR T cell therapy has revolutionized the treatment 
of several hematological malignancies and there is 
increasing focus on its potential role in solid tumors.
 ► For CAR T therapy to be effective in solid tumors, 
T cells have to traffic into the tumor, infiltrate the 
stroma and overcome a hostile TME with multiple 
metabolic, inhibitory and immunosuppressive effects.
 ► TAAs in solid tumors should be selectively and homo-
geneously expressed on tumor cells at high levels but 
not at all or at very low levels on the surface of normal 
tissues.
 ► To date, clinical trials with CAR T cells in solid tumors 
have often demonstrated severe off- tumor toxicities 
since the targeted antigens are not completely foreign 
to the host, and low expression in normal tissue can 
result in serious adverse effects.
Figure 1 Use of chimeric antigen receptor (CAR) T therapy in hematological malignancies and solid tumors. PD- L1, 
programmed death ligand-1; TIL, tumor- infiltrating lymphocyte.
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 ► CAR T therapy has many significant challenges to 
overcome in solid tumors. Although various bioen-
gineering approaches are being tested to overcome 
these obstacles, it is not yet known whether these will 
be effective (figure 2).
IMMUNOSCORE IN COLON CANCER CLINICAL PRACTICE: YES 
OR NO
Jerome Galon: yes
The importance of lymphocyte infiltration was shown as 
early as 1921 with a report that lymphocytic infiltration 
influenced postoperative longevity in gastric carcinoma. 
However, the significance of this was largely ignored until 
the impact of tumor immune infiltrate on patient survival 
in colorectal cancer was shown.6 This study was the first 
to show that the Immunoscore was highly significantly 
associated with time to disease recurrence in multivar-
iate analysis, independent of age, sex, T stage, N stage, 
microsatellite instability and existing prognostic factors.6 
Immunoscore was also the only independent param-
eter associated with overall survival (OS). The lack of a 
consensus definition was addressed by a worldwide effort 
that showed the Immunoscore assay to be an accurate and 
powerful prognostic factor.7 In a multivariate regression 
model for OS stratified by center that combined Immuno-
score with T stage, N stage, sex, Venous Emboli, Lymphatic 
Invasion, Perineural Invasion (VELIPI), histological 
grade, mucinous- colloid type, sidedness and microsatellite 
instability (MSI), Immunoscore was the most significant 
parameter.7 Immunoscore also showed the highest contri-
bution to predict survival (47.5%), in comparison to T 
stage (15.8%), N stage (15.6%), differentiation (13.9%), 
VELIPI (4.7%), sex (1.9%), MSI (0.4%), sidedness (0.2%) 
and mucinous colloid type (<0.01%) (figure 3).
The Immunoscore has clinical utility in colon cancer 
at all disease stages. In patients with stage I disease, the 
lower the Immunoscore the higher the risk of disease 
relapse, with the Immunoscore the only predictor of risk 
in multivariate analysis. Given this, patients with a low 
Immunoscore may require more careful follow- up after 
surgery. In stage II disease, the Immunoscore (low/inter-
mediate or high) was prognostic for time to recurrence.7 
In these patients, chemotherapy may be considered in 
high- risk patients and the Immunoscore may be a more 
accurate way to identify these patients. Moreover, in stage 
II patients traditionally considered as high- risk (T4N0), 
a high Immunoscore predicted low- risk of recurrence. 
Immunoscore also showed the highest contribution to 
predict relapse (76.2%). Thus, patients considered high- 
risk based on staging may actually be low- risk based on 
Immunoscore and so could avoid unnecessary chemo-
therapy. In patients with locally advanced stage III cancer, 
stratification into five risk categories based on Immuno-
score was predictive of time to recurrence. No patients 
in the highest Immunoscore category had disease recur-
rence or died over 8 years of follow- up. Thus, Immuno-
score can be used to identify patients with stage III disease 
at high- risk and also those with minimal risk, who may not 
require chemotherapy.
Figure 2 Use of chimeric antigen receptor (CAR) T in solid 
tumors: yes or no. Audience response before and after 
debate.
Figure 3 Immunoscore: relative variable contribution Immunoscore: contribution to predict survival, in comparison to T stage, 
N stage, differentiation, VELIPI, sex, microsatellite instability (MSI), sidedness and mucinous colloid type.
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In a phase III randomized study of patients with 
stage III colon cancer, a comparison of 3 vs 6 months of 
chemotherapy was inconclusive, with non- inferiority of 
3 months of therapy not confirmed.8 However, Immu-
noscore was predictive of disease- free survival (DFS) 
over 6 years, with no recurrence or deaths in the highest 
Immunoscore group.9 In patients treated with 6 months 
FOLFOX chemotherapy (Folinic acid, Fluorouracil and 
Oxaliplatin), a high Immunoscore significantly predicted 
response in all patients with stage III colon cancer as well 
as in low- risk (T1-3 and N1) and high- risk (T4 or N2) 
patients.10 In patients with stage IV disease, Immunoscore 
applied to metastases should be added to pathological 
score and molecular status for routine clinical assess-
ment. Of these three parameters, only Immunoscore had 
a significant contribution to the risk of time to recurrence 
and OS. Immunoscore also has the highest contribution 
to the risk of death in metastatic disease.
Immune markers comparable to Immunoscore have 
also been shown to be predictive of response to treatment 
in other cancers. For example, in metastatic melanoma, 
CD8+ density in the invasive margin was a better predic-
tive marker of response to anti- PD-1 therapy than PD- L1 
or other biomarkers.11
The Immunoscore stratifies patients into low- risk and 
high- risk and is the strongest prognostic parameter in 
univariate and multivariate analyses. It has been shown to 
be predictive of response to chemotherapy at all disease 
stages in colon cancer and is likely also predictive of 
response to immunotherapy. There is a strong argument 
for introducing a ‘I’ for immune into the TNM classifi-
cation of cancer. Immunoscore is an approved in vitro 
diagnostic for clinical use in colon cancer in Europe and 
there are certified laboratories in the USA and China. 
Currently, non- inclusion in treatment guidelines and 
reimbursement issues are two of the major obstacles to 
more widespread adoption.
Carlo Bifulco: no
The demonstration in 2006, that the type, density and 
location of immune cells within tumors, as quantified 
by the Immunoscore, was a better predictor of patient 
survival than histopathological methods used to stage 
colorectal cancer,6 was a major and unexpected paradigm 
change, since at the time, cancer immunotherapy was 
not a mainstream accepted therapeutic option and only 
limited pre- existing evidence was available that supported 
the role of immune infiltrates in influencing patient 
outcomes. The study clearly showed that the assessment of 
immune infiltrates is a powerful prognostic factor, poten-
tially more predictive of outcomes than traditional TNM 
staging, highlighting the need for a fundamental change 
in assessing patients with cancer that includes the host 
immune response and demonstrating that relying solely 
on tumor characteristics is insufficient to fully capture the 
biology of cancer.
Multiple subsequent publications have assessed and 
validated the Immunoscore in larger cohorts. In 2018, an 
international task force consortium assessed the Immuno-
score assay in patients with TNM stage I–III colon cancer 
and showed that it provided a robust and reproducible 
estimate of the risk of disease recurrence in patients.7 
These and other similar findings, strongly support the 
clinical and analytical validity of the Immunoscore, and 
argue for the incorporation of the Immunoscore as a 
new component of an improved TNM- Immune (TNM- I) 
cancer classification.
A critical aspect of the Immunoscore that has however 
so far prevented a wide adoption in the routine clinical 
practice is the lack of a definitive demonstration of its 
clinical utility. Although interpretations of what clinical 
utility actually is can vary, an undeniable key aspect with 
regard to the utility of biomarkers is whether they can 
predict treatment responses and thereby drive treat-
ment decision- making. This ability to predict treatment 
response is a key driver in the uptake of diagnostic assays, 
as shown by a plethora of widely adopted companion 
diagnostics that are now approved and included in the 
clinical treatment guidelines for many cancer types.
A possible explanation for the lack of a more exten-
sive exploration of the possible predictive value of the 
Immunoscore is that the dominance of the framework of 
targeted therapies, based on a relatively simple biomarker 
approach, that is, the presence or absence of the targe-
table mutation in the patients cancer, has brought to a 
very narrow interpretation of the concept of companion 
diagnostics and has discouraged the exploration of more 
complex biomarkers. A second contributing factor may 
be incidental, and possibly related to the Immunoscore 
being initially developed and best established in colon 
cancer. Colon cancer is also the cancer type where high 
MSI (MSI- H) is most frequently positive, and the Food 
and Drug Administration (FDA) accelerated approval 
of pembrolizumab for patients with MSI- H or mismatch 
repair- deficient solid tumors, granted in 2017, provided 
one of the strongest biomarkers predictive of respon-
siveness to immunotherapies that is currently available. 
Of note, this strength of MSI- H as a biomarker does not 
preclude the future possibly of incorporating the Immu-
noscore into a refined IO responsiveness assessment that 
further stratifies MSI- H patients. Another future open 
opportunity for Immunoscore is the neoadjuvant setting. 
As an example, a recent trial of neoadjuvant atezolizumab 
in urothelial carcinoma reported that the presence of 
activated CD8+ GZMB+ T cells correlated with outcome, 
whereas other emerging biomarkers, such as tumor muta-
tional burden (TMB), did not.12
A broader consideration is that Immunoscore only 
provides a snapshot of the state of the overall adaptive 
immune response to the tumor. Although this informa-
tion is extremely powerful, a deeper insight into the 
mechanisms that modulate the TME and ultimately 
enable the tumor immune evasion will be required for 
the development and rational deployment of novel 
therapeutic strategies. This deeper understanding of 
the biology of the TME is urgently needed, as there is 
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now a wide appreciation that PD- L1 and TMB status are 
by themselves not sufficient to guide immune- oncology 
therapies. As a consequence, multiple multiplexed 
multiparametric immunohistochemistry/immunofluo-
rescence platforms and strategies are currently actively 
being developed to address these questions. These novel 
platforms can enable the acquisition of a large numbers 
of phenotypic biomarkers in a spatial context, and 
could significantly impact the field, similarly to what the 
transition from Sanger to next- generation sequencing 
(NGS) recently did for genomics. Ultimately, porting 
the analytical strengths of the Immunoscore to these 
‘next- generation’ platforms tools will likely be needed 
to overcome the limitations of the current generation 
of immune- oncology biomarkers.
Key points
 ► The Immunoscore was first shown to be the only 
independent parameter associated with overall OS 
in colon cancer and a consensus definition of the 
Immunoscore was addressed by a worldwide effort 
that showed the assay to be an accurate and powerful 
prognostic factor.
 ► Various studies support the clinical and analytical 
validity of the Immunoscore and its incorporation 
as a new component of an improved TNM- I cancer 
classification.
 ► The Immunoscore has clinical utility in colon cancer 
at all disease stages and has been shown to be predic-
tive of response to chemotherapy and is likely also 
predictive of response to immunotherapy.
 ► However, the lack of a specific clinically relevant 
predictive indication for the Immunoscore may have 
limited its more widespread adoption.
 ► Immunoscore is an approved in vitro diagnostic for 
clinical use in colon cancer in Europe and there are 
certified laboratories in the USA and China.
 ► Currently, non- inclusion in treatment guidelines and 
reimbursement issues are two of the major obstacles 
to more widespread adoption (figure 4).
IS ADCC IMPORTANT FOR ANTI-CTLA-4 MODE OF ACTION? YES 
OR NO
Sergio A Quezada: yes
Anti- CTLA-4 antibodies alter the intratumoral balance 
between effector (Teff) and Treg cells and increase the 
Teff:Treg ratio. In an in vivo melanoma model, anti- 
CTLA-4 blocked the inhibitory activity of CTLA-4 anti-
bodies on Teff and Treg cells, with high levels of surface 
CTLA-4 on Treg cells relative to Teff cells promoting pref-
erential depletion of Treg cells at the tumor site.13 This 
resulted in enhanced antitumor Teff cell activity capable 
of inducing tumor regression.
The effect of anti- CTLA-4 on Tregs is dependent on 
the presence of Fcγ receptor (FcγR)- expressing macro-
phages within the TME and is natural killer (NK) and 
complement- independent.14 FcγRs are key drivers of 
ADCC. In mice, ADCC is regulated predominantly by the 
low- affinity receptors FcγRIII and FcγRIV, as well as the 
high- affinity FcγRI. Treg depletion by FcIV macrophages 
is key to the antitumor activity of anti- CTLA-4, as shown 
by the high complete response rate to anti- CTLA in wild- 
type mice, which was absent if FcIV knockout mice were 
used.
Anti- CTLA-4 has a dual Treg depletion and Teff 
blocking effect in mice, meaning ADCC is important for 
anti- CTLA-4 activity. However, while this is true for mice, 
there is no consensus of the role of ADCC in anti- CTLA-4 
activity in humans. The rules of engagement for mouse 
FcRs binding to rat or hamster IgG are different than 
those for human FcRs binding to human IgG.
In human cancers, CTLA-4 is expressed preferentially 
on tumor- infiltrating Tregs and this is shown in different 
cancer types, including melanoma, non- small- cell lung 
cancer and renal cell carcinoma. Using chimeric antimu-
rine CTLA-4 antibodies with human IgG1 to model ipili-
mumab, IgG1 wild- type antibody demonstrated superior 
ADCC activity to an IgG1 mutant isotype with no binding 
to FcγRs, while IgG1 mutant with optimized FcγR- binding 
promoted enhanced ADCC activity. The IgG1 isotype 
with enhanced ADCC promoted the depletion of tumor- 
infiltrating Tregs. Human anti- CTLA-4 IgG1 mutant 
promoted superior antitumor activity in vivo in a mouse 
model expressing human FcRs. Tumor growth was equiv-
alent in untreated mice and those treated with the Fc- si-
lent IgG1 mutant, demonstrating that CTLA-4 blockade 
alone is insufficient to promote tumor rejection in the 
context of human FcγR- IgG interactions.
In humans, evidence for a role of FcγR- mediated effector 
function in tumor- targeting antibody- based cancer thera-
pies (eg, rituximab) derives from studies demonstrating 
an association between clinical responses and activating 
FcγRs that confer higher binding affinity to IgG1. If part 
of anti CTLA-4’s activity is based on FcγR engagement and 
Treg depletion, the presence of FcR polymorphisms that 
increase affinity for IgGs should correlate with enhanced 
antitumor activity. In patients with melanoma treated 
with ipilimumab, FcR polymorphism was associated 
with an improved response to anti- CTLA-4 among those 
Figure 4 Immunoscore in clinical practice: yes or no. 
Audience response before and after debate.
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with a high mutational burden (ie, more immunogenic, 
inflamed tumor) but not those with a low mutational 
burden. More evidence for a role of ADCC in humans is 
provided by IPEX syndrome, which in effect represents 
a human model of FOXP3 knockout and the symptoms 
of which are similar to the immune- related side effects of 
anti- CTLA-4 treatment.
In conclusion, FcR engagement and Treg depletion is a 
key component of the activity of anti- CTLA-4 antibodies 
in mice. In humans, the presence of FcR polymorphism 
and high TMB correlates with increased responses to anti- 
CTLA-4. If ipilimumab is a partial Treg depleter then this 
may explain the need for high- affinity FcR polymorphism 
and, if so, then most of its toxicity is driven by blocking 
Treg activity. These data may point toward the need for a 
high- ADCC anti- CTLA-4.
John Timmerman: no
The critical question being debated is not whether Treg 
depletion during anti- CTLA-4 treatment is important but 
whether ADCC elicited by anti- CTLA-4 antibodies is clin-
ically relevant.
In the study by Laurent et al,15 CTLA-4 expression 
and ipilimumab reactivity were analyzed in melanoma 
models. However, most results were from cell lines with 
very heterogenous expression of CTLA-4, which is mostly 
intracellular and not accessible to therapeutic antibodies. 
Significant cell surface CTLA-4 expression was infrequent 
and only seen in 14% of cell lines. Moreover, cell lines 
can begin to aberrantly express antigens in vitro after 
prolonged culture. In an in vivo xenograft model, the 
co- engraftment of ipilimumab- treated melanoma cells 
with human allogeneic NK cells delayed tumor growth, 
as compared with mice receiving control xenografts. 
However, this delay was only modest and limited to the 
cell line with highest CTLA-4 expression. No data were 
reported from clinically relevant studies showing, for 
instance, correlation between response to ipilimumab 
and cell surface CTLA-4 expression.
In a study of 29 patients with advanced cutaneous mela-
noma, ipilimumab engaged ex vivo with FcγRIIIA (CD16)- 
expressing monocytes resulting in ADCC- mediated Treg 
depletion.16 However, clinical studies have shown that 
FOXP3+ Tregs are not depleted from peripheral blood 
during ipilimumab treatment.17 The study also reported 
that patients responding to ipilimumab had higher 
peripheral counts of non- classical monocytes at baseline, 
but this is only indirect evidence of ADCC involvement in 
an antitumor immune response.
In a mouse model expressing FcγRs, antibodies with 
higher FcγR binding drove superior anti- tumor responses 
and survival. However, these studies only measured FcR 
binding and not ADCC. FcR binding could simply allow, 
after binding to an NK or monocyte cell surface, greater 
avidity ligation and blocking of CTLA-4 on the surface of 
T cells, irrespective of actual ADCC. Response to ipilim-
umab in humans also correlated with CD16a- V158F poly-
morphism; however, as previously, this is only a measure of 
binding to the effector cell surface, and not actual ADCC 
or tumor cell killing in vivo. Thus, there are convincing 
data that FcR binding is important but no direct evidence 
that ADCC is involved.
Finally, even if ADCC is active in anti- CTLA-4 therapy, 
trying to engineer novel more potent anti- CTLA-4 anti-
bodies for enhanced ADCC seems unlikely to improve 
outcomes, given that 20 years of effort to improve ADCC 
in anti- CD20 antibodies in lymphoma has failed to yield 
an antibody with clearly improved efficacy over rituximab, 
an IgG1 similar to ipilimumab.
Key points
 ► FcγRs are key drivers of ADCC and FcR engagement 
and Treg depletion is a key component of the activity 
of anti- CTLA-4 antibodies in mice.
 ► In a mouse model expressing FcγRs, antibodies 
with higher FcγR binding drove superior anti- tumor 
responses and survival. However, these studies only 
measured FcR binding and not ADCC.
 ► If part of anti CTLA-4’s activity is based on FcγR 
engagement and Treg depletion, the presence of 
FcR polymorphisms that increase affinity for IgGs 
should correlate with enhanced antitumor activity. 
In humans, the presence of FcR polymorphism and 
high TMB correlates with increased responses to anti- 
CTLA-4. However, this may show that FcR binding 
is important but is not direct evidence that ADCC is 
involved.
 ► If ipilimumab is a partial Treg depleter then this may 
explain the need for high- affinity FcR polymorphism 
and, if so, then most of its toxicity is driven by blocking 
Treg activity.
 ► These data may point toward the need for a high- 
ADCC anti- CTLA-4. However, efforts to improve 
ADCC in anti- CD20 antibodies in lymphoma has 
failed to yield an antibody with clearly improved effi-
cacy over rituximab (figure 5).
Figure 5 Is antibody- dependent cellular cytotoxicity 
important for anticytotoxic T- lymphocyte- associated protein 
4 mode of action? Yes or no. Audience response before and 
after debate.
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THE BRAIN IS JUST ANOTHER ORGAN? YES OR NO
Hussein A Tawbi: yes
Patients with brain metastases greatly outnumber those 
with primary brain tumors, with up to 30% of patients 
with metastatic cancer having brain metastases at some 
point. Brain metastases are also a strong prognostic indi-
cator of very poor outcomes, with median survival of typi-
cally only 3–6 months.
In metastatic melanoma, brain metastases are an 
everyday problem in the clinic with 30%–40% of 
patients having brain metastases at the time of diagnosis, 
increasing to up to 60% during treatment and up to 80% 
at time of death. Historically, median survival of patients 
with melanoma has been approximately 8 months, with 
the presence of brain metastases reducing this to around 
4 months. Recent advances in targeted therapy and immu-
notherapy have resulted in greatly improved outcomes, 
with over 50% survival at 5 years. Pivotal phase III studies 
of these new agents have included almost 7000 patients 
with melanoma. However, patients with brain metastases 
were excluded from all these trials (figure 6). Reasons for 
this include their expected worse prognosis with imme-
diate neurological deterioration, the belief that drugs are 
unable to penetrate the brain, and the assumption that 
that brain is not immunologically responsive. There is 
also the underlying supposition that brain metastases may 
be better treated with surgery and/or radiation.
The brain is one of most protected parts of body, with 
many difficult to penetrate layers that makes access from 
the blood is limited, including an active efflux through 
the blood- brain barrier. However, many drugs can over-
come the blood- brain barrier, even though they may have 
been specifically designed not to enter the brain, for 
example, to reduce toxicity.
In a phase I trial of dabrafenib in 10 patients with 
melanoma and untreated brain metastases, changes in 
intracranial and extracranial tumor size were similar, 
with 9 patients having an intracranial response.18 In 
the BREAK- MB (melanoma with brain metastases) trial, 
which was the first to specifically enroll patients with 
melanoma with brain metastases, intracranial responses 
of 39% in patients with no previous brain treatment 
and 31% in patients with prior brain treatment were 
achieved.19 Several other trials have also since shown 
positive intracranial responses. In the COMBI- MB (mela-
noma with brain metastases) trial, dabrafenib plus trame-
tinib was active with a 60% intracranial response rate 
and a manageable safety profile in patients with BRAF 
V600- mutant melanoma with brain metastases, although 
the median duration of response was relatively short.20 
Median progression- free survival (PFS) was also shorter 
than observed in patients without brain metastases. The 
combination of encorafenib plus binimetinib may be a 
more effective targeted combination for brain metas-
tases and is being investigated using higher doses in the 
ongoing POLARIS trial.
Immunotherapy is also effective in the brain. In a 
phase II trial, ipilimumab showed activity in patients with 
advanced melanoma and brain metastases, in particular 
those who were asymptomatic and not receiving corti-
costeroids.21 Overall response rate (ORR) and PFS were 
similar with ipilimumab in patients with or without brain 
metastases. PD-1 monotherapy does appear less effective 
against brain metastases, with an intracranial response of 
22% with pembrolizumab in patients with melanoma with 
brain metastases not requiring steroids, compared with 
the 30%–40% responses rates usually seen in patients 
without brain metastases.22 However, this does not mean 
the brain should be treated differently to other organs, 
since similar response rates have been seen in liver metas-
tases with pembrolizumab. Combination immunotherapy 
may be more effective than single- agent therapy. In the 
CheckMate-204 study of nivolumab plus ipilimumab in 
patients with unirradiated brain metastases, intracranial 
and extracranial benefit was similar (57% vs 56%).23 
However, complete responses were higher in the brain. 
Responses were also durable, with intracranial progres-
sion prevented for over 6 months in 64% of patients. 
Figure 6 Pivotal stage IV melanoma trials versus melanoma brain metastases (MBM)- specific trials.
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Symptomatic patients on steroids had lower response 
rates, which may relate to steroid use rather than the pres-
ence of brain metastases. Triplet combinations of a BRAF 
inhibitor plus MEK inhibitor plus anti- PD-1/PD- L1 have 
also shown promise in patients with brain metastases.24 
Beneficial effects have also been observed with other 
treatments in patients with breast or lung cancers.
The brain is truly just another organ and, moreover, 
offers the potential for novel combinations. Checkpoint 
inhibitor therapy combined with stereotactic radiosur-
gery (SRS) was associated with decreased distant and 
local intracranial failure compared with SRS alone in 
a retrospective study of patients with melanoma25 and 
several prospective trials are ongoing to further assess this 
potential synergy. One positive consequence of this may 
be to encourage greater multidisciplinary efforts, with 
radiation oncologists working more closely with medical 
as well as neuro- oncologists in brain metastases- focused 
clinics.
Hideho Okada: no
Although checkpoint inhibition has resulted in response 
rates of over 50% in patients with melanoma with brain 
metastases,23 outcomes in patients with primary brain 
tumors have been less positive. In preliminary analysis of 
the CheckMate-143 trial, nivolumab failed to prolong OS 
of patients with recurrent glioblastoma (GBM), and this 
arm of the trial was prematurely closed.26 This poses the 
question of why there is a difference in response between 
metastatic and primary brain tumors.
GBM is more infiltrative and has been shown to 
disseminate throughout the brain and central nervous 
system (CNS), with cells found in the brain stem even 
when not originally detectable. Because of this, GBM is 
more protected by the blood- brain barrier than brain 
metastases. Penetration of IgG antibodies through the 
intact blood- brain barrier is only around 4%. There 
may also be more profound lymphopenia in recur-
rent GBM, especially after immunosuppressive stan-
dard of care chemoradiation. In addition, melanoma 
is much more immunogenic than GBM, with a higher 
TMB. However, there are some common challenges in 
primary and secondary brain tumors, including hetero-
geneity and primary/acquired resistance and common 
mechanisms of immune escape, such as heterogeneity, 
major histocompatibility complex downregulation and 
immunosuppressive molecules.
The brain is not just another organ. The idea of the 
brain as immunologically privileged dates to the first 
observation a century ago that rat sarcoma grew well when 
transplanted into the mouse brain parenchyma, but not 
when implanted into subcutaneous or muscle tissue. It was 
subsequently shown that if recipient spleen was co- trans-
planted with the foreign tumor in the brain parenchyma, 
tumor growth was inhibited. This has been attributed 
to the blood- brain barrier but, although a contributory 
factor, this is not the primary explanation. This immuno- 
privilege is relative and not absolute, is confined to the 
CNS parenchyma, applicable to both adaptive and innate 
immunity, and mostly a result of defects in the afferent 
arm in adaptive immunity.
It has been shown that cerebral spinal fluid (CSF) 
can contain T cells and CAR T cells, which is used as 
evidence that these can cross the blood- brain barrier. 
However, CSF differs from the fluid in the brain paren-
chyma, the interstitial fluid (ISF), and there is a barrier 
between the two compartments between which cells are 
not freely exchanged. Antigen- presenting cells (APCs) 
in the CSF can drain into lymph nodes, but there is 
no clear route for those in the ISF. Thus, a major part 
of the brain’s immuno- privilege is a defect in antigen 
presentation.27
With regard to the afferent arm in adaptive immu-
nity, some trafficking of T cell can occur. In an experi-
mental model, ovalbumin CD4+ T helper peptide vaccine 
promoted protective immunity via induction of CD8+ 
cytotoxic T lymphocytes (CTLs) against subcutaneous 
but not intracranial melanomas.27 Subcutaneous tumors 
responded to either class I or class II peptides, while intra-
cranial tumors did not respond to class II peptide. IHC 
revealed extensive infiltration of CD11c+ dendritic cells 
(DCs) in subcutaneous but not intracranial tumors.
There are also metabolic differences between extracra-
nial and brain metastases. Analysis of melanoma brain 
metastases and patient- matched extracranial metastases 
identified significant immunosuppression in brain metas-
tases, with reduced T cell, DC and macrophage infil-
tration and enrichment of oxidative phosphorylation 
(OXPHOS).28 OXPHOS inhibition improved survival of 
mice bearing MAPK inhibitor- resistant intracranial mela-
noma xenografts and inhibited melanoma brain metas-
tases formation.
Brain damage may also be associated with systemic 
immunosuppression. In GBM as well as other cancers 
with intracranial metastases, T cells appear to be seques-
tered to the bone marrow.29 Thus, lesions in the brain 
may suppress the systemic immune response.
Finally, the brain may be susceptible to a systemic 
immune response. Impaired antigen presentation may 
lead to lack of tolerance meaning the brain is more 
prone to autoimmunity. The brain is the only organ 
in which autoimmunity can be induced, as shown by a 
mouse model of multiple sclerosis, experimental auto-
immune encephalomyelitis. Also, in paraneoplastic 
cerebellar degeneration, peripheral activation of cdr2- 
specific CTLs is likely to contribute to the subsequent 
development of the autoimmune neuronal degen-
eration.30 Both cancer and cerebellar cells express 
a common antigen, cdr2, which triggers a systemic 
CTL response, which can be responsible for ataxia in 
patients with undiagnosed cancers (eg, ovarian cancer). 
Severe neurotoxicity events associated with adoptive T 
cell therapy also suggest an immune effect on the brain. 
TCR targeting MAGE- A3 caused severe damage to brain 
gray matter by recognizing MAGE- A12 expression in the 
brain, resulting in two deaths.31 In addition, high IL-6, 
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IL-2, granulocyte macrophage colony- stimulating factor 
and vascular endothelial growth factor levels have been 
observed in CSF during neurotoxicity, with both CD20 
CAR and non- CAR T cells accumulating in the CSF and 
in the brain parenchyma.32
In summary, immunological privilege of the brain may 
be primarily characterized by impaired antigen presenta-
tion. However, there are also other issues, such as differ-
ential metabolism and T cell sequestration to the bone 
marrow. Nonetheless, the brain (and cancer in the brain) 
can be susceptible to the systemic immune response once 
the response is primed against brain- associated antigens.
Key points
 ► Patients with brain metastases are often excluded 
from immunotherapy trials due to their expected 
worse prognosis, the belief that drugs are unable to 
penetrate the brain and the assumption that that 
brain is not immunologically responsive.
 ► Immunotherapy is effective in the brain and combi-
nation immunotherapy may be more effective than 
single- agent therapy. Nivolumab plus ipilimumab 
resulted in durable intracranial benefit in patients 
with melanoma with unirradiated brain metastases.
 ► Checkpoint inhibitor therapy combined with SRS has 
also been associated with decreased distant and local 
intracranial failure compared with SRS alone and 
several prospective trials are ongoing to further assess 
this potential synergy.
 ► However, checkpoint inhibition has been less effective 
in patients with primary brain tumors, which may be 
more infiltrative and less immunogenic than mela-
noma brain metastases.
 ► Immunological privilege of the brain may be primarily 
characterized by impaired antigen presentation but 
there are also other factors, such as differential metab-
olism and T cell sequestration to the bone marrow.
 ► Nonetheless, the brain can be susceptible to the 
systemic immune response once the response is 
primed against brain- associated antigens (figure 7).
IS THE MICROBIOME OR NUTRITION MORE IMPORTANT FOR 
RESPONSE TO IMMUNOTHERAPY?
Giorgio Trinchieri: microbiome
It is now widely accepted that the composition of the 
gut microbiome may contribute to the efficacy of cancer 
therapy, primarily by modulating the antitumor immune 
response through training infiltrating myeloid and APCs 
in distant tumors. This has shown in a series of studies, 
involving CpG- oligodeoxynucleotides, oxaliplatin, cyclo-
phosphamide, ACT and immune checkpoint inhibitors. 
Until recently, most data were from mouse models but 
several clinical studies have now suggested a role of micro-
biota composition in response to treatment, including 
anti- PD-1 therapy.33–35
However, even though there is increasing evidence 
that the microbiome has a role in response to therapy, 
we do not yet know what constitutes a favorable or unfa-
vorable microbiome. A critical question is whether we 
can somehow target the microbiome to improve thera-
peutic response. NGS and improved culture technology 
means it is now possible to better characterize the micro-
biome, with regard to identifying bacterial species that 
are present. However, modifying the microbiome is more 
difficult and various approaches have been suggested, 
including antibiotics, probiotics, prebiotics, diet and fecal 
microbial transplant (FMT).
Although several studies have indicated that micro-
biome composition influences response to anti- PD-1 
therapy, no single bacterial species has been identified 
as positively correlated with response across different 
studies. Because it is not currently known which bacteria 
should be targeted, a possible strategy is to transplant fecal 
microbiota from a patient who responds to treatment 
to a non- responding patient. FMT is being assessed in 
ongoing trials in patients with melanoma who are refrac-
tory to anti- PD-1 treatment. In an ongoing study at the 
University of Pittsburgh, patients who are non- responders 
to pembrolizumab at 12 weeks are receiving FMT from 
a responder, with promising preliminary results. Fecal 
samples are also being transplanted into germ- free mice 
to assess whether responses correlate with those seen in 
patients.
Although there is as yet no clear indication of which 
bacteria are important, another approach is the use of a 
bacterial consortium. A consortium of 11 bacterial strains 
from healthy human donor feces that induces inter-
feron (IFN)-γ-producing CD8 T cells in the intestine was 
shown to enhance the therapeutic efficacy of immune 
checkpoint inhibitors in syngeneic tumor models.36 This 
approach has the benefit of using a well characterized 
product. However, the microbiome represents a balanced 
ecological system and it is unclear how this might be 
affected by the introduction of such a consortium. 
Another potential strategy is the introduction of a single 
bacterial species that has been shown to correlate with 
response. Commensal Bifidobacterium have been shown 
to promote antitumor immunity and facilitate anti- PD- L1 
efficacy in mice37 and a trial is now ongoing in an attempt 
Figure 7 The brain is just another organ? Yes or no. 
Audience response before and after debate.
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to identify a single species that may improve response to 
therapy in melanoma.
Targeting the microbiome represents a promising 
approach. Future goals include the discovery of reli-
able microbiome- related biomarkers for prediction of 
response and stratification of patients and the identifi-
cation of favorable microbiomes for fecal transfer from 
responder patients or healthy donors. Identification 
of consortia of commensal bacteria that favor a clinical 
response and identification of perturbations (eg, through 
diet, prebiotics) able to induce or maintain a favorable 
microbiome composition will also be necessary.
Jennifer McQuade: nutrition
There is now an impressive body of evidence linking gut 
microbiota with response to immunotherapy. In contrast, 
there is very little data on the possible role of diet and 
nutrition on immunotherapy response. However, despite 
several studies identifying bacteria associated with 
improved response to anti- PD-1 therapy, there appears 
to be very limited overlap in terms of proresponse bacte-
rial species across different cohorts. This could in part 
attributed to differences in processing and sequencing 
of cultures. Other factors include geographic region and 
environmental influences, in particular diet. It may be 
that the real importance is not the particular bacterial 
species that are present, but rather their function.
Very little is known about the mechanisms by which gut 
microbiota influences antitumor immunity. Although the 
determinants of the gut microbiome has been well studied 
in other settings, what factors determine the microbiome 
in patients receiving immunotherapy has not been well 
studied to date. Gut microbiota are inherently modifi-
able, with <10% being genetically determined. Modifiable 
factors that influence the microbiome include body mass 
index, psychological factors, medications (eg, antibiotics, 
probiotics) and diet. Habitual diet is a key determinant 
of the gut microbiota, with a plant- based diet resulting in 
a microbiome with different characteristics to that seen 
with a meat- based diet.38 Gut microbiome composition 
can also be rapidly changed by switching from a high- fat, 
low- fiber diet to a low- fat, high- fiber diet or vice versa. In a 
controlled feeding study, switching to a high- fiber, low- fat 
African- style diet from a high- fat, low- fiber western- style 
diet was associated with increased saccharolytic fermen-
tation and butyrogenesis and suppressed secondary bile 
acid synthesis in an African- American cohort.39
Although there is relatively little overlap in bacteria 
identified as being proresponse to immunotherapy, many 
of the putative proresponse bacteria have strong dietary 
correlations from prior population- based studies. For 
example, many proresponse bacteria are fiber- fermenting 
bacteria which are typically present at higher abundance 
in people with higher intake of fiber- rich plant foods, 
leading to downstream production of short- chain fatty 
acids (eg, butyrate, propionate) in the gut. The interac-
tion between the production of short- chain fatty acids by 
the microbiome and the development of the gut mucosal 
layer and mucosal immunity is quite well studied but how 
this relates to antitumor immunity is less well known and 
is an area of active investigation.
The microbiota is a key mediator of the effects of a 
plant- based diet on human health, but is not the only 
one. For instance, the diet may exert a direct positive 
effect on the immune system for example, antineoplastic 
effects exerted by polyphenols. A plant- based high- fiber 
diet is consistent with current dietary recommendations 
in cancer, although these recommendations are primarily 
based on data on cancer prevention. Future studies should 
prospectively investigate the effects of dietary fiber on the 
gut microbiome and immune response in the setting of 
immune checkpoint inhibitors.
Diet should be assessed in all observational microbiome 
cohorts and both habitual diet and baseline microbiota 
may influence response to microbiome modulation inter-
ventions including FMT and probiotic use.
In conclusion, the gut microbiota and its metabolites 
may mediate the effect of diet. The function of the micro-
biome is more important than its composition and this is 
shaped by diet. Moreover, diet may have other beneficial 
effects not mediated by the microbiome. Dietary inter-
vention based on promoting a wholefood, plant- based 
high- fiber diet may be more cost- effective, acceptable 
and provide wider health benefits than approaches solely 
based on microbiome modulation.
Key points
 ► Several clinical studies have now suggested a role of 
gut microbiota composition in response to treatment, 
including anti- PD-1 therapy.
 ► Various approaches to render the microbiome more 
responsive to therapy have been suggested, including 
the use of antibiotics, probiotics, prebiotics, diet and 
FMT.
 ► Future goals include the discovery of reliable 
microbiome- related biomarkers for prediction of 
response and stratification of patients and the identi-
fication of favorable microbiomes.
 ► Although the microbiome appears to influence 
response to immunotherapy, the factors that deter-
mine the microbiome and how patients can achieve a 
proresponse microbiome are less well known.
 ► There appears to be very limited overlap in terms of 
proresponse bacterial species across different cohorts, 
which could in part be attributed to differences in 
environmental influences and in particular diet. It 
may be that the real importance is not the particular 
bacterial species that are present, but rather their 
function.
 ► Habitual diet is a key determinant of the gut micro-
biota, and gut microbiome composition can be rapidly 
changed by altering diet.
 ► The microbiota is a key mediator of the effects of diet 
on health, but is not the only one. For instance, the 
diet may exert a direct positive effect on the immune 
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system, for example, antineoplastic effects exerted by 
polyphenols (figure 8).
IS CHEMOTHERAPY IMMUNOSTIMULATORY OR 
IMMUNOSUPPRESSIVE?
Claus Garbe: immunostimulatory
It is well known that chemotherapy can be immunosup-
pressive but, conversely, under certain circumstances, 
it may have an immunostimulatory effect. Nearly all 
patients receiving cytotoxic agents broad- based chemo-
therapy will experience immunosuppression since, by 
design, chemotherapy targets rapidly dividing cells. Since 
immune system cells divide quickly, they are among the 
many targets of chemotherapy. Major clinical sequalae of 
immunosuppressive chemotherapy can include bacterial, 
viral or fungal infection.
The immunosuppressive effects of chemotherapy were 
shown by a study in patients with metastatic melanoma, in 
which adjuvant treatment with IFN-α resulted in a signifi-
cant DFS and OS benefit over observation after complete 
lymph node dissection.40 However, the addition of dacar-
bazine to IFN-α reversed the beneficial effect, that is, the 
immunostimulatory effect of IFN-α was negated by the 
immunosuppressive effect of chemotherapy.
However, in certain situations, chemotherapy may have 
a positive immunostimulatory effect when used with 
immunotherapy. Responses to adoptive cell transfer of 
autologous TILs with IL-2 is improved by pretreatment 
with lymphodepleting myeloablative cyclophosphamide 
and fludarabine chemotherapy.41 Agents such as pacli-
taxel or gemcitabine may also promote the elimination 
or inactivation of immunosuppressive Tregs or myeloid- 
derived suppressor cells (MDSCs), resulting in enhanced 
antitumor immunity.42 Treg elimination or inactivation 
by low- dose cyclophosphamide (metronomic regimen) 
or paclitaxel, which is a mitotic inhibitor that selec-
tively reduces Treg number and function while sparing 
effector T lymphocytes, can promote antitumor immu-
nity and enhance the efficacy of immunotherapy. MDSC 
elimination, inactivation and/or differentiation into 
proinflammatory cells, for example, with gemcitabine 
or fluorouracil, also enhances antitumor immunity and 
fosters the response to immunotherapy. Cytotoxic therapy 
may also promote the release of tumor antigens and 
thereby stimulate the immune response.43 Use of cyto-
toxic drugs can destroy cancer cells and thereby release 
antigens with the subsequent immune response leading 
to tumor eradication. In the absence of a response to 
checkpoint blockade, chemotherapy, for example, pacl-
itaxel and carboplatin in melanoma, can be used to 
promote tumor antigen release in order to stimulate the 
immune response.
There are only limited data on optimal regimens of 
chemotherapy in these instances and we are essentially at 
the start of learning how cytotoxic agents can be combined 
with immunotherapy. For example, the ideal duration of 
chemotherapy in these circumstances is unknown.
In summary, long- term use of chemotherapy is always 
immunosuppressive. However, chemotherapy can be used 
with adoptive T cell transfer and other immunotherapies 
for complete and incomplete myeloablation. Short- term 
administration of chemotherapy can also be used for the 
targeted removal of Tregs and MDSCs and to promote 
the immune response by antigen release.
Samir N Khleif: immunosuppressive
All chemotherapy acts on the cell cycle to damage rapidly 
dividing cells. Chemotherapeutic drugs are selected based 
on their direct cytotoxic effects on highly proliferating 
cells and cells are more sensitive to chemotherapeutic 
agents when in active phases of replication. This leads 
to an association with significant toxicities, which occur 
secondary to the effect of chemotherapy on highly prolif-
erative normal cells. Cytotoxic agents, even administered 
short- term at standard doses, can lead to severe lympho-
depletion, with greater reductions in CD4+ than CD8+ 
T cells. As an example of this issue, in 88 patients with 
primary breast cancer, lymphodepletion occurs after 
chemotherapy in the majority of patients. The levels of 
B and T cells were significantly reduced 2 weeks after 
chemotherapy and some of these cells remained signifi-
cantly depleted even 9 months after chemotherapy.44 
Chemotherapy can also affect NK cells. These kind of 
changes occur regardless of the type of regimen and was 
long- lasting after just four cycles of chemotherapy. For 
example, docetaxel has a pronounced immunosuppres-
sive effect on NK function.45 Taxanes have cell- subset 
dependent effects, suppressing T, B and NK cells while 
having a stimulatory effect on macrophages.46 Overall, 
standard doses of chemotherapy, even when given short- 
term, has a long- lasting effect on almost the whole reper-
toire of the immune system.
Chemotherapy also increases the immune- suppressive 
environment inhibiting effector cells and increasing 
negative regulators of the immune system. Bleomycin 
stimulates TGF-β-dependent expansion of Tregs and 
doxorubicin- cyclophosphamide chemotherapy increases 
levels of circulating MDSCs.47 48 Increased levels of circu-
lating MDSCs correlate with decreased T cell responses. 
Figure 8 Is the microbiome or nutrition more important for 
response to immunotherapy? Audience response before and 
after debate.
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Increased MDSCs with cyclophosphamide can attenuate 
antitumor CD4+ T cell response through the PD-1/PD- L1 
axis,49 and cyclophosphamide therapy- induced mono-
cytes possess immunosuppressive activities.
Chemotherapy can also induce intrinsic immune resis-
tance in cancer cells. Treatment of human or murine 
triple- negative breast cancer cells with cytotoxic agents 
promoted an immune evasion phenotype, with a marked 
increase in breast cancer cells expressing CD47+C-
D73+PDL1+.50 Etoposide has been shown to increase 
expression of PD- L1 on retinoblastoma cells and can 
cause T cell apoptosis by inducing T cell unresponsive-
ness, stimulating secretion of cytokines such as IL-10 
and suppressing immune response.51 Chemotherapy 
also induces nuclear factor kappa B (NF-κB) activation 
in cancer cells, which promotes the expression of cyto-
kines and chemokines that modulate the interaction 
between tumor cells and other cellular components of 
the TME.52 NF-κB activation is linked to IL-34 production 
which enhances immunosuppression of tumor- associated 
macrophages and mediates the survival of chemoresistant 
lung cancer cells.
To conclude, chemotherapy is clearly immunosuppres-
sive since it inhibits the number and function of effector 
immune cells, increased the immune suppressive envi-
ronment and induces intrinsic immune resistance in 
cancer cells.
Key points
 ► Chemotherapy is immunosuppressive since it inhibits 
the number and function of effector immune cells, 
increased the immune suppressive environment and 
induces intrinsic immune resistance in cancer cells.
 ► Overall, standard doses of chemotherapy, even when 
given short- term, have a long- lasting effect on almost 
the whole repertoire of the immune system.
 ► However, although chemotherapy is generally immu-
nosuppressive it can, under certain circumstances, 
have an immunostimulatory effect.
 ► Chemotherapy can be used with adoptive T cell 
transfer and other immunotherapies for complete 
and incomplete myeloablation.
 ► Short- term administration of chemotherapy can also 
be used for the targeted removal of immunosuppres-
sive Tregs and MDSCs and to promote the immune 
response by antigen release (figure 9).
CONCLUSIONS
Counterpoint views from leading experts on four contro-
versial clinical issues in immunotherapy today were 
presented during these Great Debate sessions. Given the 
constraints of the format and the intended nature of the 
session, each presentation was not intended as a rigorous 
assessment of the field but rather provided an opportu-
nity to highlight some important areas of debate within 
immunotherapy. It may be that there are no clear right 
or wrong answers to these questions; however, it is hoped 
that these discussions can help focus attention on these 
issues, stimulating further debate and encouraging the 
research needed to improve our understanding of immu-
notherapy and thereby further improve outcomes for 
patients.
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